South Korea Launches National Reverse-Aging Project: What Does It Mean?

When a country decides that the semiconductor industry is a national asset, we understand the step. When a country decides that artificial intelligence is a critical field for national security, that is also clear. But what happens when a country decides that aging itself is a strategic problem, on the level of weapons systems or energy imports? That is exactly what happened this week in South Korea.

On May 13, 2026, the Seoul Economic Daily reported that the South Korean government officially launched an unprecedented national-scale project, aiming to slow, and in some cases reverse, biological aging processes in the population. The Korean name is difficult to translate precisely, but in policy documents it is published in English as the National Reverse-Aging Project. This is not the announcement of a single study. It is a declaration of a multi-year national program, with budgets, goals, and designated officials.

The background is not technological; it is demographic. South Korea is the fastest-aging country in the world, even faster than Japan. At the end of 2025, it crossed the statistical threshold of a super-aged society: more than 20% of the population is 65 and older. The birth rate fell below 0.7 per woman (the lowest in the world). The conclusion in Seoul was simple: The pension system, health insurance, and workforce cannot be saved if we only manage aging. We must try to reverse it.

What Exactly is a National Reverse-Aging Project?

The project is not a single medical intervention, but a broad policy and funding framework. It combines three layers:

• Basic research, funding geroscience labs in universities, studying epigenetic clocks, cellular senescence, Yamanaka factors, stem cells.
• Clinical translation, accelerating regulatory approval pathways for drugs and treatments targeting aging processes, not just individual diseases.
• National infrastructure, an expanded Korean biobank, longitudinal tracking of older adults, laboratories for measuring biological age, and a data platform connected to the national healthcare system.

Additionally, the project defines healthy longevity (healthspan), not lifespan, as the primary goal. That is, the goal is not for citizens to live an extra two years in a wheelchair, but for them to live an extra decade independently, actively, and employed if they wish. This is an important nuance because it changes the entire incentive structure.

Mechanism: How Does a National Project Even Affect Aging?

Aging is not a single disease. It is a bundle of parallel processes: low-grade chronic inflammation (inflammaging), accumulation of zombie cells (senescent cells), DNA damage, mitochondrial decline, telomere shortening, impaired intercellular communication, and more. Until today, the medical system treated the outcomes: diabetes, Alzheimer's, cancer, osteoporosis. The Korean project offers a paradigm shift: treat the common root.

How does a government project do this in practice?

• Concentrated budget. Instead of each university chasing small grants, there is a special national fund. This enables large-scale experiments that would not be possible elsewhere.
• Standardization of biological age measurement. If every lab uses a different epigenetic clock, results cannot be compared. The project defines a uniform national measurement panel.
• Fast-track approval pathways. The Korean regulator (MFDS) has developed a dedicated pathway for treatments targeting aging, instead of forcing them to show results in a specific disease.
• Data sharing. The national healthcare system provides researchers with tracking data on millions of citizens (with privacy standards), a resource that Western countries struggle to provide.

Each of these components alone is rare in any research system. Their combination, in one country, under a government umbrella, creates momentum.

Current Evidence: What is Already Known and Who is Involved

Partner 1: KAIST and the Institute of Biological Aging

The central institution leading the scientific side is KAIST (Korea Advanced Institute of Science and Technology), which hosts a well-known group researching zombie cells and senolytics. Labs at KAIST published studies in 2024 and 2025 on new senolytic molecules that clear senescent cells in heart and kidney tissues. The budget expansion under the national project allows moving from the preclinical stage to large-scale human trials.

Partner 2: Seoul National University (SNU)

Seoul National University leads the genomics and epigenetics side. Its Center for Aging Biology specializes in the Korean epigenetic clock, a DNA methylation model calibrated to the Asian population, whose genetic variation is not always well-represented in the Horvath and GrimAge clocks developed on Western populations. The project funds the expansion of this clock and its testing on samples from hundreds of thousands of citizens.

Partner 3: The Private Biotech Sector

Korea has been emerging since 2015 as a biotech powerhouse. Companies like Samsung Bioepis, Celltrion, and LG Chem already play in the league of biological drug manufacturing. The national project now brings in dedicated geroscience startups: companies like Rejuvenate Bio Korea and Senescent Therapeutics, some in partnership with government funding, are developing senolytics, autophagy-activating molecules, and partial reprogramming following the work of the Sinclair group at Harvard.

Partner 4: The National Health Insurance Service (NHIS)

Perhaps the greatest asset is the National Health Insurance Service. A universal healthcare system with tracking data on 50 million citizens, including annual screening tests covering blood sugar, cholesterol, blood pressure, BMI, and soon to include epigenetic markers in some. This is the UK Biobank of Asia, but at the level of an entire country.

Budget and Timelines

• Five-year budget: Reported at approximately 1.5-2 billion US dollars (order of magnitude).
• Number of planned clinical trials: More than 30, between 2026-2030.
• Interim goal for 2030: Proof of at least a one-year reduction in average biological age in the older adult population over 60 participating in the national protocol.
• Strategic goal for 2040: Extending the healthspan of the average Korean by 5 years, compared to the 2025 level.

What About Japan, Singapore, China, the European Union?

The Korean step is not isolated. It is part of a quiet global race that is gaining momentum:

• Japan continues to invest heavily in stem cells (especially iPS, Yamanaka factors) and the aging institutes of RIKEN. But Japan is mainly engaged in basic research, not a unified national framework.
• Singapore launched the Centre for Healthy Longevity at NUS with generous government budgets, and has a national program for detecting biological age in older adults.
• China operates a five-year framework for longevity research, but is less transparent. It is known that enormous private capital flows into senolytic and NAD+ startups there.
• The European Union funds Horizon Europe Healthy Aging, a broad but decentralized platform among member states.
• The US leaves the private sector to lead: Altos Labs, Calico, Retro Biosciences. The NIH invests through the National Institute on Aging, but there is no unified national program on the Korean scale.

Korea is the first to explicitly declare a National Reverse-Aging Project as a policy goal. This changes the game.

The Critical Side: What Could Go Wrong?

A project of this scale also poses risks, not just promises. It is worth noting them.

• Hype outpacing science. The public might interpret a 'reverse-aging project' as an immediate solution, rather than a long-term research infrastructure. Public disappointment could harm funding within a few years.
• Inequality in access. If new treatments become available, who will receive them? Only the wealthy? Only urbanites? The project proposes universal access pathways, but implementation is in early stages.
• Regulatory risks. Fast-track approval pathways could compromise safety. Shortcuts in clinical trials have caused disasters in the past (the stem cell scandal in Korea in 2005 still casts a shadow on the national memory).
• Unaddressed demographics. Even if healthspan is extended by 5 years, it will not solve the demographic problem without an increase in birth rates or immigration. The project is part of the solution, not the entire solution.
• Ethical questions. Partial reprogramming, in the eyes of some scientists, opens the door to treatments whose long-term safety is still unclear. If the Korean regulator allows fast approvals, citizens may be exposed to treatments that have not been sufficiently studied.

It is important to emphasize: No one in the project claims we will reach 200-year lifespans. The goals are moderate, realistic, and clear: to halt functional decline in the seventh and eighth decades of life.

What Can Israel and Individuals Learn From This?

1. Aging is a strategic-policy issue, not just a medical one. Israel is also aging, albeit more slowly. Our life expectancy is among the highest in the world, but our healthspan is not necessarily. It would be worthwhile for the Ministry of Health, the Innovation Authority, and academia to discuss this seriously.
2. A local epigenetic clock. Classic Western clocks were developed on European populations. It would be beneficial to have an epigenetic clock calibrated to the Israeli population, with all its diverse origins. This is research that is feasible at a reasonable cost if there is national will.
3. Sharing health data for longevity research. The Israeli healthcare system has a vast and unique database in the world, four HMOs with decades of continuity. Utilizing it for geroscience research would keep Israel at the forefront of science.
4. On a personal level, there is no need to wait for a national project. Lifestyle factors that affect the biological clock (diet, physical activity, sleep, social engagement) are available today, without any regulatory approval. The evidence for this has actually strengthened in the past year.
5. Join or follow studies. Clinical trials on senolytics, low-dose rapamycin, metformin, NAD+, and more are also opening in Israel. Informed observers are the first to be exposed to updates.

The Broader Perspective

National projects of this scale do not start overnight. They are the product of a decade of basic research, years of internal policy discussions, and demographic pressure that ultimately forced the Korean government to decide. The real win of the project is not just in this or that molecule; it is in the declaration that aging itself is a legitimate policy target.

This is the first time a large country (45 million residents, one of the most advanced economies in the world) treats aging processes as a problem worth attacking directly, rather than just managing indirectly through treating age-related diseases. In 10 years, we will look back and see this as the first step of the era of policy geroscience.

The important question is not just whether the Koreans will succeed. The question is whether other countries, including Israel, will catch the message in time. Life expectancy is a demographic sentence. Healthy longevity is a policy choice.

References:
Seoul Economic Daily - Korea Launches National Reverse-Aging Project
KAIST - Korea Advanced Institute of Science and Technology
Seoul National University